Analyst Yanan Zhu of Wells Fargo maintained a Hold rating on Cellectis SA (CLLS – Research Report), with a price target of $3.00.
Yanan Zhu’s Hold rating for Cellectis SA is influenced by various factors. The promising First-in-Human (FIH) data for UCART20x22 in Non-Hodgkin Lymphoma (NHL) is a major point of interest. UCART20x22 demonstrated a 100% response rate in a small number of patients who had experienced 3rd line or later CD19 failure, which indicates potential for this treatment. Additionally, Cellectis’s financial position is relatively strong, with enough cash on hand and anticipated future investment to sustain operations until 2026.
However, there are uncertainties that moderate the rating. For instance, the approval of the anticipated $140 million investment from AstraZeneca is still pending, dependent on clearance from various entities including the French Ministry of Economy. The UCART20x22 study is also still in its early stages and undergoing dose escalation, so additional data is needed to confirm its efficacy. The small patient number at this stage also makes it premature to generalize the successful response rate. Therefore, Zhu has recommended a Hold rating until these uncertainties are clarified.
Zhu covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Arcturus Therapeutics, and Iovance Biotherapeutics. According to TipRanks, Zhu has an average return of -18.5% and a 31.58% success rate on recommended stocks.
See today’s best-performing stocks on TipRanks >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Cellectis SA (CLLS) Company Description:
Cellectis SA is a biopharmaceutical company, which engages in the research and development of genome engineering technology. The company operates through the following business segments: Therapeutics and Plants. The Therapeutics segment is focused on the development of products in the field of immune-oncology and of novel products outside immuno-oncology to treat other human diseases. The Plants segment focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology through its own efforts or through alliances with other companies in the agricultural market. Its therapeutic products are still in the preclinical stage which is developed for various kinds of tumors. Cellectis was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.
Read More on CLLS:
